Australia Trial Exposes Employee Doubts About Merck Vioxx Handling
This article was originally published in PharmAsia News
Executive Summary
Australia's Merck, Sharp & Dohme and its U.S. parent, Merck, were the subjects of more doubts cast in a court trial over their innocence of the consequences of their anti-arthritis drug Vioxx (rofecoxib). Plaintiff attorneys showed the jury in a federal court class action trial e-mail traffic that showed some employees expressed concerns about the drug. One was from an employee who said it was "a bit too much to swallow" that Merck was not aware of the drug's risks years earlier than it has admitted and well before it was withdrawn from the market in 2004. Merck has maintained it acted appropriately and responsibly. (Click here for more